This website is for UK Healthcare Professionals only

*Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
UK-VNCCLL-220184 | May 2022

Video library

Haematology experts provide their opinions on key areas in the treatment of CLL patients

 

The Breakfast CLLub: expert perspectives in CLL management

Patient Initiated Follow Up for Patients with CLL in Southampton

Claire Marsh, Cancer PIFU Project Lead University Hospital Southampton (UHS) discusses the implementation of patient-initiated follow-up (PIFU) programmes for patients with CLL.

Front line management for elderly patients in CLL

Dr Toby Eyre, Consultant Haematologist at the Oxford University Hospitals NHS Trust discusses the front-line management of elderly patients with CLL.

Case Study: IGHV Unmutated Patient in CLL

Dr Lisa Lowry, Consultant Haematologist at the Somerset Foundation Trust considers the role of IGVH mutational status in the management of patients with CLL.

(43 mins)

(23 mins)

(32 mins)


Holistic management in CLL

Dr Samir Agrawal, Senior Lecturer at the Queen Mary University of London and Honorary Consultant at Barts Health NHS Trust, advocates patient-empowering, holistic treatment in CLL patients.

Infection prophylaxis in CLL

Jess Pealing, Lead Haematology Specialist Pharmacist at The Christie Hospital Manchester, discusses prophylactic steps recommended for CLL patients to help prevent the development of infectious complications.

(35 mins)

(14 mins)

The Breakfast CLLub: expert perspectives in CLL management

Patient Initiated Follow Up for Patients with CLL in Southampton

Claire Marsh, Cancer PIFU Project Lead University Hospital Southampton (UHS) discusses the implementation of patient-initiated follow-up (PIFU) programmes for patients with CLL.

(43 mins)

Front line management for elderly patients in CLL

Dr Toby Eyre, Consultant Haematologist at the Oxford University Hospitals NHS Trust discusses the front-line management of elderly patients with CLL

(23 mins)

Case Study: IGHV Unmutated Patient in CLL

Dr Lisa Lowry, Consultant Haematologist at the Somerset Foundation Trust considers the role of IGVH mutational status in the management of patients with CLL

(32 mins)

Holistic management in CLL

Dr Samir Agrawal, Senior Lecturer at the Queen Mary University of London and Honorary Consultant at Barts Health NHS Trust, advocates patient-empowering, holistic treatment in CLL patients.

(35 mins)

Infection prophylaxis in CLL

Jess Pealing, Lead Haematology Specialist Pharmacist at The Christie Hospital Manchester, discusses prophylactic steps recommended for CLL patients to help prevent the development of infectious complications.

(14 mins)

CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

References

  1. VENCLYXTO Summary of Product Characteristics.
  2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
  3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.

 

 

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on [email protected]

UK-VNCCLL-230229. Date of preparation: June 2023.